


PHARMACEUTICAL 2021

BIOXYTRAN INC Rank 381 of 409





PHARMACEUTICAL 2021

BIOXYTRAN INC Rank 381 of 409

The relative strengths and weaknesses of BIOXYTRAN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOXYTRAN INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,122% points. The greatest weakness of BIOXYTRAN INC is the variable Assets, Current, reducing the Economic Capital Ratio by 519% points.

The company's Economic Capital Ratio, given in the ranking table, is -941%, being 586% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	316
Cost of Goods Sold	0
Intangible Assets	10
Liabilities, Current	2,268
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	248
Other Liabilities	0
Other Net Income	-1,212
Property and Equipment	0
Research and Development	545
Revenues	0
Selling, General and Administrative Expense	476

Output Variable	Value in 1000 USD
Assets	326
Liabilities	2,268
Expenses	1,269
Stockholders Equity	-1,941
Net Income	-2,481
Comprehensive Net Income	-2,481
Economic Capital Ratio	-941%